Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1,529 JPY | +0.72% | -4.56% | -12.08% |
2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Its low valuation, with P/E ratio at 6.33 and 9.29 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company's share price in relation to its net book value makes it look relatively cheap.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- The company is in debt and has limited leeway for investment
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last few months, analysts have been revising downwards their earnings forecast.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.08% | 236M | - | ||
+31.06% | 688B | C+ | ||
+30.35% | 588B | B | ||
-3.42% | 364B | C+ | ||
+18.02% | 326B | B- | ||
+4.27% | 285B | C+ | ||
+15.53% | 239B | B+ | ||
+10.16% | 210B | B- | ||
-8.14% | 200B | A+ | ||
+8.12% | 167B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 4554 Stock
- Ratings Fuji Pharma Co., Ltd.